1: Bradfute SB. History and impact of the mouse-adapted Ebola virus model.
Antiviral Res. 2023 Feb;210:105493. doi: 10.1016/j.antiviral.2022.105493. Epub
2022 Dec 23. PMID: 36567023.

2: Lane TR, Massey C, Comer JE, Freiberg AN, Zhou H, Dyall J, Holbrook MR,
Anantpadma M, Davey RA, Madrid PB, Ekins S. Pyronaridine tetraphosphate efficacy
against Ebola virus infection in guinea pig. Antiviral Res. 2020 Sep;181:104863.
doi: 10.1016/j.antiviral.2020.104863. Epub 2020 Jul 16. PMID: 32682926; PMCID:
PMC8194506.

3: Spengler JR, Welch SR, Ritter JM, Harmon JR, Coleman-McCray JD, Genzer SC,
Seixas JN, Scholte FEM, Davies KA, Bradfute SB, Montgomery JM, Spiropoulou CF.
Mouse models of Ebola virus tolerance and lethality: characterization of CD-1
mice infected with wild-type, guinea pig-adapted, or mouse-adapted virus.
Antiviral Res. 2023 Feb;210:105496. doi: 10.1016/j.antiviral.2022.105496. Epub
2022 Dec 22. PMID: 36567020.

4: Birungi D, Tumwine G, Kato CD, Ssekamatte T, Ocaido M, Majalija S. Knowledge,
perceptions and effects of Ebola virus disease outbreak on the pig value chain
in the agro-pastoralist district of Luwero, Central Uganda. BMC Infect Dis. 2021
Jul 9;21(1):669. doi: 10.1186/s12879-021-06337-8. PMID: 34243704; PMCID:
PMC8268591.

5: Morozov I, Monath TP, Meekins DA, Trujillo JD, Sunwoo SY, Urbaniak K, Kim IJ,
Narayanan SK, Indran SV, Ma W, Wilson WC, O'Connor C, Dubey S, Troth SP, Coller
BA, Nichols R, Martin BK, Feldmann H, Richt JA. High dose of vesicular
stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine
without horizontal transmission. Emerg Microbes Infect. 2021 Dec;10(1):651-663.
doi: 10.1080/22221751.2021.1903343. PMID: 33719915; PMCID: PMC8023602.

6: Bodmer BS, Gre√üler J, Schmidt ML, Holzerland J, Brandt J, Braun S, Groseth A,
Hoenen T. Differences in Viral RNA Synthesis but Not Budding or Entry Contribute
to the In Vitro Attenuation of Reston Virus Compared to Ebola Virus.
Microorganisms. 2020 Aug 11;8(8):1215. doi: 10.3390/microorganisms8081215. PMID:
32796523; PMCID: PMC7463789.

7: Zhang Y, Wei Y, Li Y, Wang X, Liu Y, Tian D, Jia X, Gong R, Liu W, Yang L.
IgY antibodies against Ebola virus possess post-exposure protection in a murine
pseudovirus challenge model and excellent thermostability. PLoS Negl Trop Dis.
2021 Mar 12;15(3):e0008403. doi: 10.1371/journal.pntd.0008403. PMID: 33711011;
PMCID: PMC7990235.

8: Dowall SD, Kempster S, Findlay-Wilson S, Mattiuzzo G, Graham VA, Page M,
Hewson R, Almond N. Towards quantification of protective antibody responses by
passive transfer of the 1st WHO International Standard for Ebola virus antibody
in a guinea pig model. Vaccine. 2020 Jan 10;38(2):345-349. doi:
10.1016/j.vaccine.2019.10.009. Epub 2019 Oct 24. PMID: 31668821.

9: Johnson DM, Juelich T, Zhang L, Smith JK, Kalveram BK, Perez D, Smith J,
Grimes MR, Garron T, Torres M, Massey S, Brasel T, Beasley DWC, Freiberg AN,
Comer JE. Comparison of Routes of Administration, Frequency, and Duration of
Favipiravir Treatment in Mouse and Guinea Pig Models of Ebola Virus Disease.
Viruses. 2024 Jul 9;16(7):1101. doi: 10.3390/v16071101. PMID: 39066263; PMCID:
PMC11281331.